The Complex Journey of Drug Development

The impact of massive multiplexing on drug development is transformative. Historically, drug screening has faced a crucial limitation: researchers must choose between testing many drugs or getting detailed cellular responses, but rarely both. ScalePlex’s massive multiplexing technology shatters this trade-off, allowing us to see the entire biological picture at once. 

Before a single pill reaches a patient's hands, it undergoes a complex journey spanning roughly 10-15 years and costs exceeding billions of dollars. This journey begins with target discovery to identify the molecular mechanisms driving disease and testing of thousands of compounds to find those that effectively interact with the target.  

These foundational experimentation steps determine the success of preclinical testing and clinical trials, with 90% of the latter ultimately failing due to suboptimal target selection. 

Why Single Cell RNA Sequencing Matters 

Traditional bulk RNA sequencing provides averaged data across millions of cells – like trying to understand traffic patterns by looking at aerial photos where individual cars blur together. More and more researchers are turning to single cell RNA sequencing to provide crucial granularity that impacts all stages of the drug development process.

Figure 1: Drug development and single cell

• Mechanism Insights: Understanding precisely how drugs affect different cell types guides optimization and reveals new therapeutic opportunities. 
• Heterogeneous Responses: Not all cells respond identically to drugs. Some may develop resistance, while others might activate unexpected pathways. 
• Safety Assessments: Detailed cellular responses help predict potential side effects before clinical trials. 

This pre-print from Sarah Teichmann’s team shows that genes with cell-type-specific expression in disease-relevant tissues are significantly more likely to progress successfully through Phase I and II clinical trials (Dann et al 2024 medRxiv doi: 10.1101/2024.04.04.24305313). This suggests that targeting cell-type-specific genes may lead to safer, more effective treatments. 

Breaking Through the Scale Barrier   

Every day, pharmaceutical researchers face a mounting challenge: thousands of potential drugs await testing, while countless patients await treatments. Traditional screening methods force scientists to choose between depth and breadth – either analyze fewer samples thoroughly or more samples superficially. This trade-off has long bottlenecked drug development, driving up costs and slowing the delivery of life-saving treatments to patients. 

High-Throughput Drug Screening with Scale Bio   

Scale Bio’s ScalePlex technology enables massive multiplexing that transforms weeks of traditional sample processing into an elegantly streamlined protocol spanning just days, demonstrated by the following drug screen study. The process begins with systematic drug treatment with a panel of 40 FDA-approved targeted oncology drugs and sample fixation across four timepoints. At time zero, researchers fix and pool the first set of 96 samples in under an hour, immediately preserving them at -80°C. This efficient processing repeats at 4 hours, 24 hours, and 48 hours, with each timepoint's samples similarly fixed and stored. The preservation of samples allows researchers to align their analysis temporally while maintaining sample integrity. 

Figure 2: Workflow of drug screening with ScalePlex

The true power of this approach emerges in the library preparation phase, where all 384 fixed samples undergo simultaneous processing over just 1.5 days. This unified processing strategy dramatically reduces technical variation while simplifying sample handling of 384 samples down to 4 representative samples. The results speak to both the efficiency and quality of the approach—over 98,000 cells profiled with cellular resolution revealing more than 2,000 genes and 3,000 unique transcripts per cell. Expected cellular responses to the BCL-ABL inhibitors included in the panel of drug treatments were observed through a sharp decline in the number of recovered cells and decreased cell viability over time, validating the accuracy of ScalePlex multiplexing.  

Figure 3: Cell recovery post drug treatment 

This technological advancement fundamentally reshapes the scale and scope of single cell studies. By compressing weeks of traditional processing into days while maintaining superior data quality, the workflow enables researchers to undertake ambitious studies that were previously impractical due to time and resource constraints. The ability to process hundreds of samples simultaneously while preserving temporal resolution opens new possibilities for understanding dynamic cellular responses across diverse experimental conditions. 

AI and Multiplexing: A Powerful Partnership    

Organizations are leveraging this technological synergy to accelerate drug discovery using AI. The convergence of AI and massive multiplexing technology is shattering previous limitations in single cell analysis, and real-world impact is already emerging. The Human Cell Atlas project is leveraging these technologies to create comprehensive maps of human cell types, while the Chan Zuckerberg Initiative is developing AI tools to create virtual cell models to better understand how to identify and treat disease. The ability to generate vast, high-quality datasets through multiplexing feeds AI systems with the comprehensive data they need to make accurate predictions. This creates a powerful feedback loop: better data leads to better AI predictions, which in turn guide more targeted experiments. 

Looking Forward 

As multiplexing technology becomes more accessible and AI systems more sophisticated, we're entering an era of unprecedented scale in drug discovery. The combination promises to accelerate therapeutic development while reducing costs—ultimately bringing better treatments to patients faster. 

The biological symphony is playing, and now we can finally hear—and understand—every note, transforming how we discover and develop the next generation of therapeutics. 

Want to read more about our recent study described above? Download the app note.